Stockscreener 앱 받기
211.90
0.02%
-0.044
전일 마감가:
$211.86
열려 있는:
$212.25
하루 거래량:
1.05M
Relative Volume:
0.19
시가총액:
$374.30B
수익:
$58.33B
순이익/손실:
$3.73B
주가수익비율:
100.91
EPS:
2.1
순현금흐름:
$18.24B
1주 성능:
+1.87%
1개월 성능:
+7.41%
6개월 성능:
+1.95%
1년 성능:
+7.51%
1일 변동 폭
$211.66
$214.19
1주일 범위
$207.90
$214.19
52주 변동 폭
$163.81
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
211.88 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
743.53 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.90 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
128.65 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.21 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Genmab/AbbVie’s Epkinly Could Get Competitive Edge With Outpatient Option - insights.citeline.com
AbbVie Beats Employee’s Would-Be Whistleblower Suit on Appeal - Bloomberg Law News
Will AbbVie Inc. bounce back from current supportEarnings Risk Summary & High Accuracy Trade Signal Alerts - Newser
Multiple Myeloma Market Size Projected USD 49.89 Billion by 2034 - GlobeNewswire Inc.
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
AbbVie reports positive results for outpatient lymphoma treatment - Investing.com
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Investing News Network
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - PR Newswire
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers - AbbVie News Center
Intraday pattern recognizer results for AbbVie Inc.Market Trend Report & Verified Stock Trade Ideas - Newser
Stock Analysis | Abbvie OutlookMixed Signals Amid Optimistic Analysts and Strong Fundamentals - AInvest
Quantitative breakdown of AbbVie Inc. recent moveTrade Signal Summary & Daily Profit Maximizing Tips - Newser
Combining machine learning predictions for AbbVie Inc.Stop Loss & Fast Gaining Stock Strategy Reports - Newser
AbbVie’s Strategic Acquisitions and Trial Success Fuel 0.72% Rally Despite 102nd-Ranked 920M Volume - AInvest
Strategic Implications of AbbVie’s Elahere Approval in Canada: A New Era for Oncology Growth and Market Access - AInvest
AbbVie's Elahere gains approval in Canada for ovarian cancer - Seeking Alpha
Visual trend scoring systems applied to AbbVie Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - Newser
AbbVie HIV Drugs Being Tested as Possible Coronavirus Antidote - TheStreet
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Investing News Network
Candlestick signals on AbbVie Inc. stock today2025 Trade Ideas & Fast Gain Swing Alerts - Newser
AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market - MSN
Explore the human side of the health journey in AbbVie’s I Am campaign - Medical Marketing and Media
Visual analytics tools that track AbbVie Inc. performanceFed Meeting & Real-Time Sentiment Analysis - Newser
AbbVie to invest $195 million in new North Chicago pharmaceutical facility - Chicago Construction News
AbbVie (ABBV) Stock Analysis: Price Target & Market OutlookNews and Statistics - IndexBox
Is AbbVie Inc. backed by strong institutional buyingInsider Buying & AI Enhanced Market Trend Forecasts - خودرو بانک
Is AbbVie Stock Underperforming the S&P 500? - MSN
How to escape a deep drawdown in AbbVie Inc.2025 Big Picture & Real-Time Price Movement Reports - Newser
Analyzing recovery setups for AbbVie Inc. investorsGDP Growth & Fast Gain Stock Trading Tips - Newser
Analyzing drawdowns of AbbVie Inc. with statistical toolsTrade Exit Summary & Verified Stock Trade Ideas - Newser
Why AbbVie's Workplace Excellence Drives Long-Term Value for Investors - AInvest
Key metrics from AbbVie Inc.’s quarterly dataInflation Watch & Target Return Focused Picks - Newser
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work - Yahoo Finance
What indicators show strength in AbbVie Inc.2025 Retail Activity & Verified Entry Point Signals - Newser
What recovery options are there for AbbVie Inc.2025 Stock Rankings & Smart Money Movement Tracker - Newser
Pharma and Industrial Sector Catalysts: Evaluating AbbVie and Hawkins' Strategic Momentum - AInvest
What machine learning models say about AbbVie Inc.Weekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Signal strength of AbbVie Inc. stock in tech scannersMarket Volume Summary & Free Verified High Yield Trade Plans - Newser
Tools to assess AbbVie Inc.’s risk profile2025 Top Gainers & Technical Pattern Based Signals - Newser
Key deals this week: Hawkins, Canada Goose, AbbVie, Verint and more (BX:NYSE) - Seeking Alpha
Is AbbVie Inc. trending in predictive chart models2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Is AbbVie Stock Underperforming The S&P 500? - Barchart.com
BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory - insights.citeline.com
Detecting price anomalies in AbbVie Inc. with AIWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
0.33%
자본화:
|
볼륨(24시간):